Secondary malignancies after hematopoietic stem cell transplantation.
Advances in the field of hematopoietic stem cell transplantation have led to an increasing number of cures of malignant and non-malignant diseases with this therapeutic approach. Long-term survivorship may, however, be associated with secondary malignancies, the result of a complex interaction of treatment-, recipient- and immunosuppression-related factors. Furthermore, the increasing use of donors other than human leukocyte antigen-identical siblings is associated with more intense immunosuppression, delayed immune recovery and higher incidence of B-cell post-transplantation lymphoproliferative disorders. Here, we review the incidence and the risk factors associated with these complications of hematopoietic stem cell transplants.
Department of Blood and Marrow Transplantation of the University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 423, Houston, TX 77030, USA.
Dipak
D
Ghelani
Rima
R
Saliba
Marcos de
Md
Lima
D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects* / Q000379:methods; D015994:Incidence; D009369:Neoplasms / Q000209:etiology* / Q000473:pathology* / Q000503:physiopathology; D012307:Risk Factors; D017741:Survivors; D014019:Tissue Donors